학술논문
Dosimetry and optimal scan time of [18 F]SiTATE-PET/CT in patients with neuroendocrine tumours.
Document Type
Article
Author
Beyer, Leonie; Gosewisch, Astrid; Lindner, Simon; Völter, Friederike; Mittlmeier, Lena M.; Tiling, Reinhold; Brendel, Matthias; Cyran, Clemens C.; Unterrainer, Marcus; Rübenthaler, Johannes; Auernhammer, Christoph J.; Spitzweg, Christine; Böning, Guido; Gildehaus, F. J.; Jurkschat, Klaus; Wängler, Carmen; Wängler, Björn; Schirrmacher, Ralf; Wenter, Vera; Todica, Andrei
Source
Subject
*NEUROENDOCRINE tumors
*RADIATION dosimetry
*SOMATOSTATIN receptors
*INJECTIONS
*ADULTS
*OPTICALLY stimulated luminescence
*
*
*
*
*
Language
ISSN
1619-7070
Abstract
Purpose: Radiolabelled somatostatin analogues targeting somatostatin receptors (SSR) are well established for combined positron emission tomography/computer tomography (PET/CT) imaging of neuroendocrine tumours (NET). [18F]SiTATE has recently been introduced showing high image quality, promising clinical performance and improved logistics compared to the clinical reference standard 68Ga-DOTA-TOC. Here we present the first dosimetry and optimal scan time analysis. Methods: Eight NET patients received a [18F]SiTATE-PET/CT (250 ± 66 MBq) with repeated emission scans (10, 30, 60, 120, 180 min after injection). Biodistribution in normal organs and SSR-positive tumour uptake were assessed. Dosimetry estimates for risk organs were determined using a combined linear-monoexponential model, and by applying 18F S-values and reference target masses for the ICRP89 adult male or female (OLINDA 2.0). Tumour-to-background ratios were compared quantitatively and visually between different scan times. Results: After 1 h, normal organs showed similar tracer uptake with only negligible changes until 3 h post-injection. In contrast, tracer uptake by tumours increased progressively for almost all types of metastases, thus increasing tumour-to-background ratios over time. Dosimetry resulted in a total effective dose of 0.015 ± 0.004 mSv/MBq. Visual evaluation revealed no clinically relevant discrepancies between later scan times, but image quality was rated highest in 60 and 120 min images. Conclusion: [18F]SiTATE-PET/CT in NET shows overall high tumour-to-background ratios from 60 to 180 min after injection and an effective dose comparable to 68Ga-labelled alternatives. For clinical use of [18F]SiTATE, the best compromise between image quality and tumour-to-background contrast is reached at 120 min, followed by 60 min after injection. [ABSTRACT FROM AUTHOR]